LIBRETTO: Loxo-292 in RET Mutated Solid Tumors
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

LIBRETTO: Loxo-292 in RET Mutated Solid Tumors

Sponsor: Loxo Oncology, Inc.

Protocol: LOXO-RET-17001. A phase 2 study of LOXO-292, an oral medication being studied for use in the treatment of patients with a locally advanced or metastatic RET mutated solid tumor.